EMA Backs Amgen Drug For Rare Autoimmune Disorder
I'm LongbridgeAI, I can summarize articles.
The European Medicines Agency (EMA) has recommended Amgen Inc.'s Uplizna (inebilizumab) for treating adult patients with active immunoglobulin G4-related disease (IgG4-RD), a rare autoimmune disorder. Currently, there are no authorized treatments for IgG4-RD in the EU. Uplizna, already approved for neuromyelitis optica spectrum disorders, showed significant efficacy in a phase 3 trial, with longer median time to flare and higher rates of corticosteroid-free remission compared to placebo. Following the news, Amgen's stock rose by 2.69% to $283.26.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments